Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Hematoxylin compounds can selectively kill CALR mutant cancer cells

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

Combination of venetoclax and standard therapies shows promise in high-risk myeloid blood cancers

Donor stem cell transplant can improve survival rates for older patients with MDS, study shows

Donor stem cell transplant can improve survival rates for older patients with MDS, study shows

Study sheds light on the high burden of late effects among young survivors of acute myeloid leukemia

Study sheds light on the high burden of late effects among young survivors of acute myeloid leukemia

Beat AML trial achieves primary endpoint

Beat AML trial achieves primary endpoint

Advancements in research on cancer signal transduction and treatment

Advancements in research on cancer signal transduction and treatment

UVA research sheds light on how cancer remodels our chromosomes

UVA research sheds light on how cancer remodels our chromosomes

Study analyzes link between clonal hematopoiesis and treatment-related blood cancer risk

Study analyzes link between clonal hematopoiesis and treatment-related blood cancer risk

SARS-CoV-2 infection of carotid arteries may explain vascular involvement in COVID-19

SARS-CoV-2 infection of carotid arteries may explain vascular involvement in COVID-19

Researchers identify a potential target for small cell lung cancer

Researchers identify a potential target for small cell lung cancer

MD Anderson and Astex Pharmaceuticals partner to accelerate clinical evaluation of leukemia therapies

MD Anderson and Astex Pharmaceuticals partner to accelerate clinical evaluation of leukemia therapies

Researchers identify new mechanism that causes leukemia

Researchers identify new mechanism that causes leukemia

Combination regimen improves overall survival in certain patients with AML

Combination regimen improves overall survival in certain patients with AML

Powerful treatment for IPF stops dangerous scar formation in mouse lungs

Powerful treatment for IPF stops dangerous scar formation in mouse lungs

ASH publishes new guidelines to help tailor treatment for older adults with acute myeloid leukemia

ASH publishes new guidelines to help tailor treatment for older adults with acute myeloid leukemia

Study could refine treatment recommendations for younger adult patients with acute leukemia

Study could refine treatment recommendations for younger adult patients with acute leukemia

Study reveals impact of TP53 gene mutations on MDS severity

Study reveals impact of TP53 gene mutations on MDS severity

Study sheds light on potential new treatment approach in AML patients

Study sheds light on potential new treatment approach in AML patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.